Overview

Oxaliplatin in Unresectable Hepatocellular Carcinoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary: - To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin Secondary: - Safety and tolerability of this regimen in these patients
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Oxaliplatin